FAMU Names Ken Redda Vice President for Research
News Jun 07, 2014
Florida A&M University (FAMU) President Elmira Mangum, Ph.D., has appointed K. Ken Redda, Ph.D., vice president for research.
Redda, a professor of medicinal chemistry in the FAMU College of Pharmacy and Pharmaceutical Sciences, served as interim vice president for research since 2010. He previously served as the associate vice president for Research from 2004 to 2005 and currently serves as an activity leader for the Drug Discovery Core Facility, a component of the FAMU Research Center in Minority Institutions Program. His research focuses on the design and synthesis of nitrogen heterocycles as anti-inflammatory and anti-cancer agents.
During his 29-year tenure at FAMU, Redda has generated more than $36.5 million in research and training grant awards, garnered multiple patents and has received numerous awards for his outstanding achievements in teaching, research and service, including the prestigious Teaching Incentive Program Award, the Professorial Excellence Program Award and the Special Recognition Award for his exceptional contributions in the area of grantsmanship by former FAMU President Fred Gainous.
He was also named FAMU's “Advanced Teacher of the Year” in 2010 and the “Best Male Faculty Member" at the 2013 Historically Black Colleges and Universities (HBCU) Awards.
Redda, the author of “Cocaine, Marijuana, Designer Drugs: Chemistry, Pharmacology and Behavior,” has published approximately 60 scientific peer-reviewed and indexed papers and his research findings have been presented at nearly 100 national and international scientific meetings throughout the United States, North America, Europe, Africa and Asia.
Redda received his Ph.D. in medicinal chemistry from the Faculty of Pharmacy at the University of Alberta (Canada). He joined the FAMU faculty in 1985 as an associate professor of medicinal chemistry after serving as an assistant professor of medicinal chemistry at the University of Puerto Rico's College of Pharmacy in San Juan from 1980-1984.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Deadly Mushroom Toxin Helps Fight Cancer?News
The death-cap mushroom has a long history as a tool of murder and suicide, going back to ancient Roman times. While it may seem ill-advised, researchers are eager to synthesize the toxin because studies have shown that it could help fight cancer. Scientists now report how they overcame obstacles to synthesize the death-cap killer compound.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018